drugset / Trial / NCT02241369
Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase I, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3106 alone or in combination with INO-9012 DNA vaccines delivered by Electroporation to subjects with HPV6 associated aerodigestive precancerous lesions and malignancies.
Timeline
- Start
- 2014-05
- Primary completion
- 2018-09
- Completion
- 2018-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INO-3106 | Vaccine | 6 mg | Other |
| Subject | Rocakinogene Sifuplasmid | Vaccine | 1 mg | Other |